[Skip to Content]
[Skip to Content Landing]
Editorial
February 2016

Prognostic Tests for Estrogen Receptor–Positive Breast CancerNeed for Global Consideration and Further Evolution

Author Affiliations
  • 1Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
  • 2Department of Breast Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
  • 3Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea
  • 4Division of Pathology, NSABP Foundation, Pittsburgh, Pennsylvania
JAMA Oncol. 2016;2(2):180-182. doi:10.1001/jamaoncol.2015.4343

The NSABP B-31 trial testing the efficacy of adjuvant trastuzumab was almost derailed right after launching because 18% of the enrolled patients were found to be ERBB2-negative (formerly HER2 or HER2/neu) on central review of the initial 104 patients.1 This prompted international efforts to improve reliability of ERBB2 testing, eventually leading to American Society of Clinical Oncology/College of American Pathologists Guideline for HER2 Testing. Ironically, OncotypeDx owes its creation to this event.

First Page Preview View Large
First page PDF preview
First page PDF preview
×